Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449562 | 0.90 | MAPT (0.51) | MAPTGAARAB9ANPC1ALDH1A1 | |
| SCHEMBL13783472 | 0.87 | GAA (0.45) | MAPTGAARAB9ANPC1ALDH1A1 | |
| SCHEMBL20809148 | 0.83 | MAPT (0.41) | MAPTGAAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4494838 | 0.81 | POLB (0.41) | MAPTRAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL4407103 | 0.81 | GAA (0.43) | MAPTGAARAB9ANPC1ALDH1A1 | |
| SCHEMBL4479813 | 0.80 | ALDH1A1 (0.42) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL20937675 | 0.80 | MEN1 (0.47) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL14813742 | 0.80 | LMNA (0.43) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12945380 | 0.77 | ALDH1A1 (0.41) | MAPTRAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL21426176 | 0.77 | HSD11B1 (0.40) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | MAPT 4633/4885GAA 2424/4885RAB9A 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.